Process Controls in PCR: Internal Amplification Controls and Their Role in Validation

Internal amplification controls (IACs) are known quantities of nucleic acid added to each PCR reaction to monitor for inhibition, reaction failure, and amplification efficiency. An IAC is co-amplified with the target sequence using either the same primers (competitive IAC) or a distinct primer pair (non-competitive IAC), and its signal indicates whether a negative result reflects true absence of target or a failed reaction. IACs are essential when testing complex biological samples—such as blood, soil, plant tissue, or formalin-fixed paraffin-embedded (FFPE) material—that may contain PCR inhibitors. They are also critical in multiplex assays where multiple targets are interrogated simultaneously, as demonstrated in the development of a qPCR multiplex array for viral detection in breast cancer tissue [1]. Use IACs whenever a negative result could have serious consequences, such as in pathogen detection, genetic screening, or forensic analysis.

At a Glance

Scientific Principle of Internal Amplification Controls

The fundamental principle underlying IACs is that PCR inhibitors—substances that interfere with DNA polymerase activity, primer annealing, or template denaturation—can produce false-negative results. Common inhibitors include heme from blood, humic acids from soil, polysaccharides from plant tissues, formalin from fixed specimens, and various organic compounds. An IAC provides a built-in positive control within every reaction tube, allowing the user to verify that amplification occurred even when the target is absent.

In competitive IAC design, the control template uses the same primer binding sites as the target but produces a distinguishable amplicon (different size or internal sequence). The control and target compete for the same primers, so their relative concentrations must be carefully balanced. In non-competitive IAC design, the control uses a different primer pair and template, often from an exogenous source such as a synthetic oligonucleotide or a plasmid containing a unique sequence. Non-competitive IACs do not compete with the target for primers but may still compete for polymerase and nucleotides.

The choice between competitive and non-competitive IAC depends on the application. Competitive IACs more accurately reflect inhibition of the target amplification because they use identical primer sequences. However, they require careful titration to avoid suppressing target amplification. Non-competitive IACs are easier to optimize and can be added at a fixed concentration, but they may not detect inhibition that specifically affects the target primer pair.

Materials and Instrumentation Considerations

Template Selection for IAC

The IAC template must be stable, quantifiable, and distinguishable from the target. Common options include:

• Synthetic oligonucleotides (gBlocks or similar): Double-stranded DNA fragments of defined sequence, typically 100–500 bp. These are highly pure and can be quantified by spectrophotometry. The study validating a qPCR multiplex array used gBlocks Gene Fragments at 10 ng/µL as positive controls for each target virus [1].

• Plasmid DNA: Cloned target sequence with a modified internal region or a completely unrelated sequence. Plasmids are stable and can be produced in large quantities.

• In vitro transcribed RNA: For RT-PCR applications, RNA IACs control for both reverse transcription and PCR steps.

• Genomic DNA from a different species: For example, using plant DNA as an IAC in human pathogen detection, provided the primers do not cross-react.

Primer Design for IAC

For competitive IACs, design the control template to produce an amplicon that is either larger or smaller than the target amplicon by at least 50–100 bp for gel-based detection. For qPCR, use a different fluorophore (e.g., FAM for target, HEX or VIC for IAC) with distinct emission spectra.

For non-competitive IACs, select primer sequences that have no homology to the target or sample genome. Common choices include primers targeting synthetic sequences or genes from organisms unlikely to be present in the sample (e.g., plant genes in human samples).

Instrument Compatibility

Most real-time PCR instruments can detect at least 4–5 fluorophores simultaneously, allowing multiplex detection of target and IAC. Ensure that the instrument's optical configuration supports the chosen fluorophore combination. For end-point PCR with gel electrophoresis, the IAC amplicon must be resolvable from the target amplicon by size.

Controls and Experimental Design

IAC Placement in the Workflow

The IAC should be added to every reaction tube, including standards and no-template controls (NTCs). In the NTC, the IAC signal confirms that the master mix is functional and that contamination is absent. In sample reactions, the IAC signal indicates whether inhibition is present.

Concentration Optimization

The IAC concentration must be optimized to avoid two extremes:

• Too high: The IAC may outcompete the target (competitive IAC) or consume reagents (non-competitive IAC), reducing target sensitivity.
• Too low: The IAC may fail to amplify consistently, especially in the presence of mild inhibition.

A typical starting point is 100–1000 copies per reaction for qPCR, adjusted based on the target's expected concentration. For competitive IACs, the control should be present at a concentration that does not suppress the target's limit of detection. This is determined empirically by spiking known amounts of target into reactions with varying IAC concentrations.

Multiplex Considerations

When using IACs in multiplex assays, ensure that the IAC primers and probe do not interfere with target amplification. The study developing a qPCR multiplex array for 21 viral sequences likely required careful optimization of IAC placement to avoid cross-reactivity [1]. Test each primer pair individually and in combination to verify that amplification efficiency remains within acceptable ranges (90–110% for qPCR).

Conceptual Workflow

Step 1: Design and Synthesis

1. Select IAC type (competitive or non-competitive) based on application.
2. Design IAC template sequence and primers.
3. Synthesize or purchase IAC template (gBlocks, plasmid, or oligonucleotide).
4. Verify IAC sequence by Sanger sequencing.

Step 2: Optimization

1. Determine optimal IAC concentration by testing a dilution series (e.g., 10, 100, 1000, 10,000 copies/reaction).
2. For competitive IACs, test target detection limit in the presence of IAC.
3. For qPCR, verify that IAC and target amplification efficiencies are similar (slope difference <0.1).
4. Confirm that IAC does not amplify in NTC (no contamination).

Step 3: Validation

1. Test IAC performance with known positive and negative samples.
2. Assess reproducibility across runs (inter-assay CV <5% for Ct values).
3. Evaluate inhibition detection by spiking samples with known inhibitors (e.g., 0.1% SDS, 1% ethanol, or 10 µM EDTA).
4. Document acceptance criteria (e.g., IAC Ct within ±2 cycles of expected value).

Step 4: Routine Use

1. Add IAC to master mix at optimized concentration.
2. Include IAC in every reaction, including standards and NTCs.
3. Monitor IAC signal in each run.
4. Flag samples where IAC signal is absent or delayed beyond acceptance criteria.

Quality Checks and Acceptance Criteria

For qPCR

• IAC Ct value: Should fall within a predefined range (e.g., 28–32 cycles). Values outside this range indicate inhibition or reaction failure.
• IAC amplification curve: Should show exponential amplification with proper baseline and threshold settings.
• IAC melt curve (if using SYBR Green): Should produce a single, sharp peak at the expected melting temperature.
• No-template control: IAC should amplify normally; target should not amplify.

For End-Point PCR

• IAC band: Should be visible at the expected size in all reactions, including NTCs.
• Band intensity: Should be consistent across reactions (±20% by densitometry).
• No-target control: IAC band present; no target band.

Acceptance Criteria Example

These criteria align with the validation parameters reported for the qPCR multiplex array, which demonstrated R² >0.98 and amplification efficiencies within 90–110% [1].

Result Interpretation

Scenario 1: Target Positive, IAC Positive

Interpretation: Successful amplification. The target is present, and the reaction was not inhibited. This is the expected outcome for positive samples.

Scenario 2: Target Negative, IAC Positive

Interpretation: True negative. The target is absent, and the reaction was functional. This result is reliable.

Scenario 3: Target Negative, IAC Negative or Delayed

Interpretation: Inhibition or reaction failure. The result is invalid. The sample should be diluted, purified, or re-extracted. If inhibition persists, consider using a different DNA extraction method or adding PCR enhancers (e.g., BSA, betaine, DMSO).

Scenario 4: Target Positive, IAC Negative or Weak

Interpretation: Possible target competition (competitive IAC) or high target concentration consuming reagents. If the IAC is competitive, this may be acceptable if the target signal is strong and the IAC failure is due to competition rather than inhibition. For non-competitive IACs, this pattern suggests inhibition that preferentially affects the IAC primer pair, which is rare but possible.

Scenario 5: Both Target and IAC Negative

Interpretation: Complete reaction failure. Check master mix, thermal cycler, and sample preparation. Repeat the assay.

Troubleshooting

Limitations and Considerations

Competitive IAC Limitations

Competitive IACs can suppress target amplification when the target concentration is low. This is particularly problematic in diagnostic applications where detecting low copy numbers is critical. The IAC concentration must be carefully titrated to balance inhibition detection with sensitivity.

Non-Competitive IAC Limitations

Non-competitive IACs may not detect inhibition that specifically affects the target primer pair. For example, if a sample contains a substance that binds to the target primers but not the IAC primers, the IAC will amplify normally while the target fails. This scenario is uncommon but possible.

Sample-Specific Considerations

• FFPE samples: DNA from FFPE tissue is often degraded and may contain formalin-induced crosslinks. The study on red deer sex determination redesigned ZFY primers to yield a short amplicon suitable for compromised templates [4]. IACs for FFPE samples should produce short amplicons (<200 bp) to match the target's amplification characteristics.

• Dried blood spots (DBS): DBS samples may contain inhibitors from blood components. The newborn screening study for spinal muscular atrophy used DBS samples and likely incorporated IACs to monitor inhibition [2].

• Plant tissues: Plant samples contain polysaccharides and polyphenolics that inhibit PCR. The LAMP assay for Cronartium ribicola detection in pine samples required optimization to overcome these inhibitors [3].

• Soil and environmental samples: Humic acids are potent PCR inhibitors. IACs are essential for these samples, and additional purification steps may be necessary.

Multiplex Assay Complexity

As the number of targets increases, IAC design becomes more challenging. The qPCR multiplex array targeting 21 viral sequences required careful validation to ensure that the IAC did not interfere with any target amplification [1]. In such assays, consider using multiple IACs or a single IAC with a unique fluorophore that does not overlap with target channels.

Documentation and Reporting

Laboratory Records

Document the following for each IAC lot:

• IAC template source and sequence
• Concentration and storage conditions
• Optimization data (titration curves, efficiency calculations)
• Acceptance criteria and validation results
• Lot-to-lot variability assessment

Run Records

For each PCR run, record:

• IAC type and concentration
• IAC Ct values for all reactions
• Any samples where IAC failed acceptance criteria
• Corrective actions taken (dilution, re-extraction, etc.)

Reporting Results

When reporting results, indicate:

• Whether IAC was used
• Acceptance criteria applied
• Any samples with IAC failure and how they were handled
• Confidence in negative results based on IAC performance

Biosafety Considerations

BSL-1 Practice

For routine teaching and research applications using non-pathogenic organisms or synthetic templates, follow standard BSL-1 practices as outlined in the Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition [5]:

• Use dedicated lab coats and gloves
• Decontaminate work surfaces before and after procedures
• Use aerosol-resistant pipette tips
• Dispose of PCR products and IAC templates as biohazardous waste if they contain recombinant DNA

Recombinant DNA Considerations

If the IAC template is constructed using recombinant DNA techniques (e.g., cloning into plasmids), follow the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules [6]. Most IAC constructs fall under exempt or minimal risk categories, but institutional biosafety committee (IBC) approval may be required.

Synthetic Nucleic Acids

Synthetic IAC templates (gBlocks, oligonucleotides) that do not encode functional proteins or pathogenic sequences generally pose minimal risk. However, verify that the sequence does not inadvertently encode a toxin or virulence factor. The NIH Guidelines apply to synthetic nucleic acids that can replicate or encode gene products [6].

Decontamination

PCR products and IAC templates should be decontaminated before disposal. Common methods include:

• 10% bleach (sodium hypochlorite) for 30 minutes
• Autoclaving at 121°C for 30 minutes
• Commercial DNA decontamination solutions

Frequently Asked Questions

1. Can I use the same IAC for different target assays?

Yes, provided the IAC primers and template do not interfere with the new target assay. Test the IAC in combination with the new primers to verify no cross-reactivity or competition. Non-competitive IACs with unique primer sequences are more portable across assays than competitive IACs.

2. How do I know if my IAC concentration is optimal?

Perform a titration experiment where you add decreasing amounts of target DNA to reactions containing a fixed IAC concentration. The optimal IAC concentration is the highest concentration that does not suppress the target's limit of detection. For qPCR, the IAC Ct should be stable (±1 cycle) across target concentrations spanning the assay's dynamic range.

3. What should I do if my IAC consistently fails in a particular sample type?

First, verify that the sample DNA is pure (A260/A280 1.8–2.0, A260/A230 >1.5). If inhibition is confirmed, try diluting the sample 1:5 or 1:10, which often reduces inhibitor concentration without losing target detection. Alternatively, use a different DNA extraction method designed to remove inhibitors (e.g., column-based purification with inhibitor removal steps). Adding PCR enhancers such as bovine serum albumin (BSA, 0.1–0.5 µg/µL) or betaine (0.5–1 M) can also help.

4. Is an IAC necessary for every PCR reaction, or can I use a separate control tube?

An IAC should be in every reaction tube, not just a separate control tube. The purpose of the IAC is to monitor inhibition in each individual sample. A separate control tube only tells you that the master mix is functional, not whether a particular sample contains inhibitors. The only exception is when the IAC significantly compromises target sensitivity and cannot be optimized; in that case, use a separate inhibition control plate with spiked samples.

References and Further Reading

1. Del Carmen Trujillo-Murillo K, Lugo-Trampe A, Rodríguez-Sánchez IP, et al. Development and validation of a quantitative pcr array assay for the detection of viral sequences in breast cancer. 2026. PubMed — Describes validation of a qPCR multiplex array with gBlocks positive controls, demonstrating R² >0.98 and 90–110% amplification efficiency.

2. Coliban I, Usurelu N, Opalco I, et al. Newborn Screening for Spinal Muscular Atrophy in the Republic of Moldova: A Feasibility Study and First Steps. 2026. PubMed — Reports SMA screening using DBS samples with qPCR, highlighting operational integration of molecular testing.

3. Zhang X, Peng Z, Jing R, et al. Establishment of a Visual LAMP Technology and Detection of Cronartium ribicola Infecting Chinese White Pine in Southwestern China. 2026. PubMed — Develops a LAMP assay for plant pathogen detection, demonstrating sensitivity improvements over conventional PCR.

4. Zacharski M, Pieczka K, Dzimira S. A Case of Disorder of Sex Development in Red Deer (Cervus elaphus). 2026. PubMed — Provides practical example of short amplicon PCR design for degraded FFPE DNA.

5. CDC and NIH. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th Edition. U.S. Department of Health and Human Services, 2020. CDC — Authoritative principles for laboratory biosafety and risk assessment.

6. National Institutes of Health. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. NIH — Framework for recombinant DNA research oversight.

7. National Center for Biotechnology Information. NCBI Bookshelf: Molecular Biology and Laboratory Methods. NCBI — Searchable collection of molecular biology methods references.

Related Articles

• Touchdown PCR: Reducing Nonspecific Amplification
• Hot Start PCR: Mechanism and Benefits for Specific Amplification
• PCR Troubleshooting: No Amplification or Weak Bands
• Understanding Positive Controls in PCR: Purpose, Selection, and Interpretation
• Understanding RFU in qPCR: Relative Fluorescence Units and Their Role in Quantification
• Negative Controls in PCR and qPCR: Why They Matter and How to Set Them Up